

Jeremy J. Johnson, PharmD, PhD

Business Address

University of Illinois at Chicago
College of Pharmacy
Department of Pharmacy Practice (MC 886)
833 S. Wood Street
Chicago, Illinois 60612
TEL: (312) 996-4368
FAX: (312) 996-0379
jjjohn@uic.edu

Education

- 1997 – 2001 **Bachelor of Science (B.S.)**
University of Wisconsin-Stevens Point (UWSP)
College of Letters and Science
Major: Biology
Minor: Chemistry
- 2003 – 2007 **Doctor of Pharmacy (Pharm.D.)**
University of Wisconsin-Madison
School of Pharmacy
Major: Pharmacy
- 2007 – 2010 **Doctor of Philosophy (Ph.D.)**
University of Wisconsin-Madison
School of Veterinary Medicine
Major: Comparative and Biomedical Sciences
Emphasis: Cancer Chemoprevention / Translational Research
Advisor: Hasan Mukhtar, PhD
Thesis title: Selected plant constituents for the prevention and treatment of prostate cancer

Honors and Awards

- 2001 University of Wisconsin-Stevens Point (UWSP), Dean's Distinguished Achievement Award
- 2007 TEAM Scholar, University of Wisconsin-Madison
- 2007 – 2010 CTSA Scholar, University of Wisconsin-Madison
- 2008 Susan G. Komen AACR Scholar-In-Training Award
Frontiers in Cancer Prevention Research, November 16-19th, National Harbor MD
- 2009 Susan G. Komen AACR Scholar-In-Training Award
Frontiers in Cancer Prevention Research, December 6-9th 2009, Houston TX
- 2011 – 2015 NIH Loan Repayment Program
- 2015 Best Oral Presentation, International Conference on Natural Products for Cancer
Prevention and Therapy (August 31st – September 2nd, Istanbul Turkey)
- 2015 Hans W. Vahlteich UIC Research Scholar
- 2019 - 2023 NCI MERIT Award

Pharmacy/Pharmacist Positions

2003 – 2004 Pharmacy Technician, Inpatient. Meriter Hospital, Madison, WI
2004 – 2006 Pharmacy Technician. Walgreens, Middleton WI
2006 Pharmacist Intern, Inpatient. Froedtert Memorial Lutheran Hospital, Milwaukee, WI
2007 – 2010 Staff Pharmacist. Walgreens, Waunakee WI
2010 – Present Clinical Pharmacist. University of Illinois at Chicago College of Pharmacy

License / Certifications

2007 – Present Registered Pharmacist (R.Ph.)
State of Wisconsin (Active) License: 15101-040 (October 2007)
2009 Certificate: Pharmacy-Based Immunization Delivery (APHA)
2011 – Present Registered Pharmacist (R.Ph.)
State of Illinois (Active) License: 051294759 (March 2011)

RESEARCH**Publications (Accepted)**

(Corresponding/Senior Author underlined)

1. **Johnson JJ**, Mukhtar H. Curcumin for chemoprevention of colon cancer. *Cancer Letters*. 2007; 255(2):170-81. PMID: 17448598
2. Pomplun M, **Johnson JJ**, Johnston S, Kolesar JM. Stability of a heparin-free 50% ethanol lock solution for central venous catheters. *Journal of Oncology Pharmacy Practice*. 2007;13:33-7. PMID: 17621565
3. Saleem M, Kweon MH, **Johnson JJ**, Adhami VM, Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw S, Spiegelman VS, Setaluri V, Mukhtar H. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. *Proceedings of National Academy of Sciences U S A*. 2006;103:14825-30. PMID: 16990429
4. **Johnson JJ**, Syed DN, Heren CR, Suh Y, Adhami VM, Mukhtar H. Carnosol, a dietary diterpene, displays growth inhibitory effects in human prostate cancer PC3 cells leading to G2-phase cell cycle arrest and targets the 5'-AMP-activated protein kinase (AMPK) pathway. *Pharmaceutical Research*. 2008;25:2125-34. PMID: 18286356
5. Suh Y, Afaq F, **Johnson JJ**, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF- κ B signaling pathways. *Carcinogenesis*. 2009;30:300-7. PMID: 19037088
6. Saleem M, Murtaza I, Tarapore R, Suh Y, Adhami VM, **Johnson JJ**, Siddiqui IA, Khan N, Asim M, Hafeez BB, Shekhani MT, Li B, Mukhtar H. Lupeol Inhibits Proliferation of Human Prostate Cancer Cells by Targeting Growth Factor Receptor / β -catenin Signaling Network. *Carcinogenesis*. 2009;30:808-17. PMID: 19233958
7. **Johnson JJ**, Bailey H, Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: A translational perspective. *Phytomedicine*. 2010;17:3-13. PMID: 19959000
8. **Johnson JJ**, Syed DS, Suh Y, Heren CR, Saleem M, Siddiqui IA, Mukhtar H. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. *Cancer Prevention Research*. 2010;3:1112-23. PMID: 20736335
9. Syed DN, Afaq F, Maddodi N, **Johnson JJ**, Sarafaz S, Ahmad A, Setaluri V, Mukhtar H. Inhibition of human melanoma cell growth by dietary flavonoid fisetin is associated with disruption of Wnt/ β -catenin signaling and decreased Mitf levels. *Journal of Investigational Dermatology*. 2011;131(6):1291-9. PMID: 21346776
10. **Johnson JJ**. Carnosol: a promising anti-cancer agent. *Cancer Letters*. 2011; 305(1):1-7. PMID: 21382660
11. **Johnson JJ**, Minakshi N, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine. *Molecular Nutrition and Food Research*. 2011;55(8):1169-76. PMID: 21714124
12. **Johnson JJ**, Syed DS, Rasmussen JT, Adhami V, Siddiqui IA, Kohl A, Mukhtar H. α -Mangostin, a xanthone from mangosteen fruit, inhibits CDK4 leading to G1 cell cycle arrest in prostate cancer and decreases xenograft tumor growth. *Carcinogenesis* 2012;33(2):413-9. PMID: 22159229
13. Ramaiya A, Li G, Petiwala SM, **Johnson JJ**. Single dose oral pharmacokinetic profile of α -mangostin in mice. *Current Drug Targets*. 2012;13:1698-704. PMID: 23140281

14. Petiwala SM, Puthenveetil AG, **Johnson JJ**. Polyphenols from the Mediterranean herb rosemary (*Rosmarinus officinalis*) for prostate cancer. *Frontiers in Pharmacology*. 2013;4:29-33. PMID: 23531917
15. Gongbo Li, Thomas SP, **Johnson JJ**. Polyphenols from the mangosteen (*Garcinia mangostana*) fruit for prostate and breast cancer. *Frontiers in Pharmacology*. 2013;4:80-83. PMID: 23805102
16. Siddique H, Adhami VM, Parray A, **Johnson JJ**, Siddiqui IA, Shekhani MT, Murtaza I, Amartsumian N, Konety BR, Mukhtar H, **Saleem M**. S100A4 promotes prostate tumorigenesis through the activation of RAGE/NFkappaB circuitry: Studies in tumor cells, human Patients and transgenic mouse model. *Genes and Cancer*. 2013;4(5-6):224-34. PMID: 24069509
17. Gongbo L, Petiwala SM, Pierce DM, Nonn L, **Johnson JJ**. Selective modulation of endoplasmic reticulum stress markers in prostate cancer cells by a standardized mangosteen fruit extract. *PLoS One*. 2013 Dec 18;8(12):e81572-e18581. PMID: 24367485.
18. Petiwala SM, Berhe S, Li G, Puthenveetil AG, Rahman O, Nonn L, **Johnson JJ**. Rosemary (*Rosmarinus officinalis*) extract modulates CHOP/GADD153 to promote androgen receptor degradation and decreases xenograft tumor growth. *PLoS One*. 2014 Mar 5;9(3):e89772-e89774. PMID: 24598693.
19. Petiwala SM, Li G, Ramaiya A, Kumar A, Gill RK, Saksena S, **Johnson JJ**. Pharmacokinetic characterization of mangosteen (*Garcinia mangostana*) fruit extract standardized to α -mangostin in C57BL/6 mice. *Nutrition Research*. 2014;34(4):336-45. PMID: 24774070.
20. Ng V, **Johnson JJ**, **Puri SC**. Targeting the mTOR pathway with everolimus: implications for the management of metastatic breast cancer. *Journal of Oncology Pharmacy Practice*. *Journal of Oncology Pharmacy Practice*. 2014;21(6):433-42. PMID: 24964967.
21. Li G, Petiwala SM, Nonn L, **Johnson JJ**. Inhibition of CHOP accentuates the apoptotic effect of α -mangostin from the mangosteen fruit (*Garcinia mangostana*) in 22Rv1 prostate cancer cells. *Biochemical and Biophysical Research Communications*. 2014;453(1):75-80. PMID: 25261723.
22. Yan M, Li G, Petiwala SM, **Johnson JJ**. Standardized rosemary (*Rosmarinus officinalis*) extract induces Nrf2/sestrin-2 pathway in colon cancer cells. *Journal of Functional Foods*. 2015;13:137-147
23. Petiwala SM, **Johnson JJ**. Diterpenes from rosemary (*Rosmarinus officinalis*): Defining their potential for anti-cancer activity. *Cancer Letters*. 2015;367(2):93-102 PMID: 26170168.
24. Petiwala SM, Li G, Bosland MC, Lantvit DD, Petukhov PA, **Johnson JJ**. Carnosic acid promotes degradation of the androgen receptor and is regulated by the unfolded protein response pathway in vitro and in vivo. *Carcinogenesis*. 2016; 37 (8): 827-838. doi: 10.1093/carcin/bgw052
25. Li G, Petiwala SM, Yan M, Petukhov P, **Johnson JJ**. Gartanin, an isoprenylated xanthone from *Garcinia mangostana*, is an androgen receptor degradation enhancer in prostate cancer cells. *Molecular Nutrition and Food Research*. 2016; 60(6):1458-69. doi: 10.1002/mnfr.201600037.
26. Yan M, Vemu B, Veenstra J, Petiwala SM, **Johnson JJ**. Carnosol, a dietary diterpene from rosemary (*Rosmarinus officinalis*) activates Nrf2 leading to sestrin 2 induction in colon cells. *Integrative Molecular Nutrition*. 2018; 5 (4): 1-7 doi: 10.15761/IMM.1000335.
27. Nauman MC, **Johnson JJ**. Clinical application of bergamot (*Citrus bergamia*) for reducing high cholesterol and cardiovascular disease markers. *Integrative Food, Nutrition, and Metabolism*. 2019; 6 (2):v1-7. doi: 10.15761/IFNM.1000249.
28. Veenstra JP, **Johnson JJ**. Oregano (*Origanum vulgare*) extract for food preservation and improvement in gastrointestinal health. *Int J Nutr*. 2019;3(4):43-52

29. Sweiss K, Calip GS, **Johnson JJ**, Rondelli D, Patel PR. Pre-transplant hemoglobin and creatinine clearance correlate with treatment free survival after autologous stem cell transplantation for multiple myeloma. *Bone Marrow Transplant*. 2019;54(12):2081-2087 doi: 10.1038/s41409-019-0628-8.
30. Vemu B, Nauman MC, Veenstra JP, **Johnson JJ**. Structure activity relationship of xanthenes from mangosteen (*Garcinia mangostana*) for inhibition of Cyclin Dependent Kinase 4. *Int J Nutr*. 2019;4(2):38-45. PMID: PMC6667231
31. Sweiss K, Vemu B, Calip GS, Wenzler E, Galvin JP, Mahmud N, Rondelli D, **Johnson JJ**, Patel P. Development of a Method for Clinical Pharmacokinetic Testing to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant. *British Journal of Clinical Pharmacology*. *Br J Clin Pharmacol*. 2020 Nov;86(11):2165-2173. doi: 10.1111/bcp.14308.
32. Tocmo R, Pena-Fronteras J, Calumba KF, Mendoza M, **Johnson JJ**. Valorization of pomelo (*Citrus grandis Osbeck*) peel: A review of current utilization, phytochemistry, bioactivities and mechanisms of action. *Comprehensive Reviews in Food Science and Food Safety*. 2020; 19 (4): 1969-2012
33. Nauman MC, Tocmo R, Vemu B, Veenstra JP, **Johnson JJ**. Inhibition of CDK2/CyclinE1 by xanthenes from the mangosteen (*Garcinia mangostana*): A structure-activity relationship study. *Natural Products Research*. 2020 Jul 21;1-5. doi: 10.1080/14786419.2020.1777413.
34. Tocmo R, Veenstra JP, Huang Y, **Johnson JJ**. Covalent modification of proteins by plant-derived natural products: Proteomics approaches and biological impacts. *Proteomics*. 2021 Feb;21(3-4):e1900386. doi: 10.1002/pmic.201900386.
35. Tocmo R, Le B, Heun A, van Pijkeren JP, Parkin K, **Johnson JJ**. Prenylated xanthenes from mangosteen (*Garcinia mangostana*) activate the AhR and Nrf2 pathways and protect intestinal barrier integrity in HT-29 cells. *Free Radic Biol Med*. 2021 Feb 1;163:102-115. doi: 10.1016/j.freeradbiomed.2020.11.018.
36. Veenstra JP, Vemu B, Tocmo R, Nauman MC, **Johnson JJ**. Pharmacokinetic Analysis of Carnosic Acid and Carnosol in Standardized Rosemary Extract and the Effect on the Disease Activity Index of DSS-Induced Colitis. *Nutrients*. 2021 Feb 27;13(3):773. doi: 10.3390/nu13030773.
37. Gaba RC, Khabbaz RC, Muchiri RN, Morrison JD, Elkhadragey L, Totura WM, Samuelson JP, Whiteley HE, Deaton RL, Nguyen PL, Sverdlov M, **Johnson JJ**, van Breemen RB, Lokken RP. Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. *Drug Deliv Transl Res*. 2021 Apr 16. doi: 10.1007/s13346-021-00985-8.
38. Bailey HH, **Johnson JJ**, Lozar T, Scarlett CO, Wollmer BW, Kim K, Havinghurst T, Ahmad N. A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol. *Eur J Cancer Prev*. 2021 May 1;30(3):285-290. doi: 10.1097/CEJ.0000000000000621.
39. Veenstra JP, **Johnson JJ**. Rosemary (*Salvia rosmarinus*): Health-Promoting Benefits and Food Preservative Properties. *Int J Nutr*. 2021;6(4):1-10. PMID: 34651071 PMID: PMC8513767
40. Vemu B, Tocmo R, Nauman MC, Flowers SA, Veenstra JP, **Johnson JJ**. Pharmacokinetic characterization of carnosol from rosemary (*Salvia rosmarinus*) in male C57BL/6 mice and inhibition profile against human cytochrome P450 enzymes. *Toxicol Appl Pharmacol*. 2021. 15;431:115729. doi: 10.1016/j.taap.2021.115729. PMID: 34592323
41. Huang Y, Tocmo, Nauman MC, Haughan MA, **Johnson JJ**. Defining the cholesterol lowering mechanism of bergamot (*Citrus bergamia*) extract in HepG2 and Caco-2 cells. *Nutrients*. 2021 Sep 10;13(9):3156. doi: 10.3390/nu13093156. PMID: 34579033 PMID: PMC8469228

42. Vemu B, Nauman MC, Flowers SA, Veenstra JP, **Johnson JJ**. Single dose oral pharmacokinetics of rosmarinic acid from rosemary (*Salvia rosmarinus*) in male C57BL/6 mice. *Toxicol Appl Pharmacol.* 2021 Nov 15;431:115729. doi: 10.1016/j.taap.2021.115729. PMID: 34592323
43. Nauman MC, **Johnson JJ**. The purple mangosteen (*Garcinia mangostana*): Defining the anticancer potential of selected xanthenes. *Pharmacol Res.* 2021 Dec 9:106032. doi: 10.1016/j.phrs.2021.106032. PMID: 34896543
44. Gurgul A, Nauman MC, Wu Z, Shetye G, Ma R, Youn I, Souliya O, Bisson J, Johnson JJ, Che CT. Chemical constituents of the stem of *Marsypopetalum modestum* and their bioactivities. *Nat Prod Res.* 2022 Jul 12:1-8. doi: 10.1080/14786419.2022.2097229. PMID: 35819993

Publications (Submitted / In prep)

(Corresponding/Senior Author underlined)

1. Tocmo R, Nauman MC, Johnson JJ. Isoprenylated xanthenes from mangosteen (*Garcinia mangostana*) tinctures inhibit LPS-1induced pro-inflammatory responses in macrophages through activation of Nrf2. (In prep)
2. Huang Y, Johnson JJ. Clinical application of berberine for reducing high cholesterol and biological markers of cardiovascular disease. (In prep)

Book Chapters

1. **Johnson JJ**. Natural Products for Colon Cancer Chemoprevention. In M. Schwab (Ed.), Encyclopedia of Cancer. 2nd Edition., 2009

Invention Disclosures

1. **Johnson JJ**. Absorption of α -mangostin is enhanced when administered with other xanthenes in the mangosteen fruit. *Experimental proof of concept exists. Submission 03/24/2014
2. **Johnson JJ**. Xanthenes from the mangosteen as modulators of endoplasmic reticulum stress in normal and diseased cells. *Experimental proof of concept exists. Submission 03/24/2014
3. **Johnson JJ**. Gartanin from the mangosteen fruit (*Garcinia mangostana*) is an androgen receptor degradation enhancer. *Experimental proof of concept exists. Submission 03/28/2014

Invited Oral Presentations, Colloquia and Symposia

International

1. **Johnson JJ.** High dose resveratrol in human subjects over 84 days: Implications on plasma levels of resveratrol. 15th International Conference of ISANH (International Society of Antioxidants for Nutrition and Health) Antioxidants. June 23rd, 2015. Paris, France; Pasteur Institute
2. **Johnson JJ.** High Dose Phytochemicals in Clinical Trials: Friend or Foe? 10th Congress of the International Society of Nutrigenetics and Nutrigenomics. May 22-26th 2016. Tel Aviv, Israel.
3. **Johnson JJ.** Pharmacokinetics of Phytochemicals: Implications for Clinical Trial Design. American Council for Medicinally Active Plants – 7th Annual Conference. June 29th – July 1, 2016. Lima, Peru.
4. **Johnson JJ.** Xanthenes from the mangosteen fruit as androgen receptor degradation Enhancers. Pathology Congress. July 8-9, 2017. Rome, Italy
5. **Johnson JJ.** How to use clinical knowledge to direct translational research. 8th International Xiangya Clinical Pharmacy Forum. September 8, 2018. Changsha China
6. **Johnson JJ.** Discovering new pharmacotherapy strategies inspired by natural products. Harvest Pharmaceuticals, September 10, 2018 in Changsha, China
7. **Johnson JJ.** Using the mangosteen fruit as inspiration for anti-androgen drug discovery. Hunan University of Traditional Chinese Medicine. September 11, 2018. Changsha, China
8. **Johnson JJ.** Using the mangosteen fruit as inspiration for anti-androgen drug discovery. Innovations in Food Science and Human Nutrition. September 13-15, 2018. Rome, Italy.
9. **Johnson JJ.** Disrupting androgen receptor with xanthenes from the mangosteen fruit. ISANH (International Society of Antioxidants for Nutrition and Health) 11th World Congress on Polyphenols Applications. University of Vienna. June 20-21st 2017. Vienna, Austria
10. **Johnson JJ.** Southeast Asian Mangosteen (*Garcinia mangostana*) Fruit as a Lead for Drug Discovery. Conference on Pharmacology and Pharmaceutical Medicine. February 14, 2019
11. **Johnson JJ.** Health Promoting Properties of Phytochemicals from Rosemary (*Rosmarinus officinalis*) for Cancer and Inflammatory Bowel Disease. Conference on Applications of Preventive Nutrition. February 18, 2019 Rome, Italy.
12. **Johnson JJ.** Phytochemicals, biological activity and dosing considerations. University of Santo Tomas. September 11, 2019. University of Santo Tomas, Manila, Philippines.
13. **Johnson JJ.** Mangosteen fruit and selected xanthenes to disrupt prostate cancer. University of Santo Tomas. September 11, 2019. University of Santo Tomas, Manila, Philippines.
14. **Johnson, JJ.** Mangosteen (*Garcinia mangostana*) fruit and selected xanthenes to disrupt prostate cancer. Presentation type: Oral Presentation. 3rd International Conference on Natural Products for Cancer Prevention and Therapy at Erciyes University. December 18-20, 2019. Kayseri, Turkey
15. **Johnson, JJ.** Anti-cancer activity and pharmacokinetic properties of natural products 4th International Conference on Natural Products for Cancer Prevention and Therapy at Erciyes University. December 18-19, 2021. Kayseri, Turkey

National

1. **Johnson JJ.** International Conference on Nutrition Science and Therapy in Philadelphia, PA July 15-17th 2013 titled, "Rosemary polyphenols as a natural alternative to synthetic preservatives: Implications for cancer chemoprevention".
2. **Johnson JJ.** 52nd Annual Meeting, Phytochemical Society of North America in Corvallis, OR August 3-7, 2013. "Deconstructing the rosemary plant to characterize its anti-cancer activity"
3. **Johnson JJ.** "Health promoting properties of rosemary polyphenols." October 17th, 2013 Sabinsa Corporation. Lehi, Utah
4. **Johnson JJ.** Pharmacy Based Clinical and Translational Science: Opportunities for Innovative Practice and Research-Clinical Research Opportunities for Pharmacists" American College of Clinical Pharmacy Annual Meeting in Albuquerque, NM, October 13th – 16th, 2013.
5. **Johnson, JJ.** Considerations for Therapeutic Drug Monitoring and Pharmacokinetics with Phytochemicals. 10th Annual American Council on Medicinally Active Plants Conference. June 24-25, 2021. Hosted by Rutgers (Virtual Conference)
6. **Johnson JJ,** Rodriguez, RR, Patel S, Siblini H, Al Hendy A, Segars J, Singh B, Taylor H, Flores V, Gonzalez F, Christman G, Huang H, Zhang H. Development of a Novel Multiplex Pharmacokinetic Assay to Simultaneously Quantify Multiple Green Tea Catechins, Letrozole and Clomiphene in Human Plasma in the PreFRIEND Clinical Trial. 68th Annual Meeting of the Society for Reproductive Investigation. June 6-9, 2021. Boston, MA

Local

1. **Johnson JJ.** "Dietary Xanthenes from the Mangosteen Fruit for Prostate Cancer" University of Illinois at Chicago Gastrointestinal (GI) nutrition disorders seminar. April 11th, 2012
2. **Johnson JJ.** "Dual disruption of androgen and estrogen receptors for prostate cancer" University of Illinois at Chicago Biopharmaceutical Sciences seminar. April 10th, 2012
3. **Johnson JJ.** Overcoming Research Pitfalls. CCTS UIC Bootcamp. July 10th, 2013
4. **Johnson JJ** University of Illinois at Chicago Carcinogenesis and Chemoprevention Program. "CHOPing the androgen receptor with rosemary polyphenols". November 14, 2013
5. **Johnson JJ.** Overcoming Research Pitfalls. CCTS UIC Bootcamp. July 10th, 2014
6. **Johnson JJ.** Applied Pharmacognosy: What a pharmacist needs to know. David Slatkin Symposium. Chicago State University. Chicago, IL November 18, 2016.
7. **Johnson JJ.** Discovering New Pharmacotherapy Strategies Inspired by Natural Products. University of Wisconsin-Madison. March 6, 2018
8. Alan Lau and **Johnson JJ.** Alternative Medicine Clinical Trials. Conference on Integrative Medicine at UIC Center for Global Health, Colleges of Medicine and Pharmacy. Chicago, IL September 24th, 2015
9. **Johnson JJ.** Evaluating the mangosteen fruit for disrupting prostate cancer. Northern Michigan University. Medicinal Plant Chemistry Department Seminar. April 3, 2019
10. **Johnson JJ.** Discovering new pharmacotherapy strategies inspired by natural products. UIC International Pharmacy Program. Chicago, IL July 17, 2019

11. **Johnson JJ.** Navigating the Grant Funding and Grant Submission Process. UIC Department of Pharmacy Practice, Department Seminar. Chicago, IL February 19, 2020
12. **Johnson JJ.** Research Panel and Q&A on Grants and Contracts. UIC Department of Pharmacy Practice, Department Seminar. Chicago, IL September 15, 2021

Research Abstracts and Poster Presentations

1. Saleem M, Murtaza, Suh Y, **Johnson JJ**, Adhami VM, Hafeez BB, Siddiqui IA, Asim M, Mukhtar M. Lupeol inhibits proliferation by modulating the growth factor receptor and Wnt signaling in human prostate cancer cells. 99th Annual AACR Meeting, April 12-16th, 2008; San Diego, CA (Poster)
2. **Johnson JJ**, Syed DS, Adhami V, Mukhtar H. Carnosol, a dietary diterpene, displays growth inhibitory effects in human prostate cancer PC3 cells leading to G2-phase cell cycle arrest and targets the 5'-AMP-activated protein kinase (AMPK) pathway. AACR annual Conference. 2008; Denver CO. (Poster)
3. Johnson JJ, Syed DS, Heren CR, Siddiqui IA, Mukhtar H. Carnosol, a dietary diterpene functions as a dual AR and ER- α antagonist in prostate cancer. AACR Frontiers in Cancer Prevention, 2008. (Poster)
4. Handa H, Rasmussen JT, **Johnson JJ**. Dietary Xanthenes from the Mangosteen Fruit Decrease Prostate Cancer Cell Viability. University of Wisconsin Undergraduate Research Symposium. April 16, 2009; Madison, WI. (Poster)
5. Saleem, Adhami VM, Murtaza I, **Johnson JJ**, Siddiqui IA, Talha M, Tarapore RS, Khaja S, Asim M, Hafeez BB, Mukhtar H. Intracellular and Extra-cellular Role of S100A4, a calcium binding protein, in Development and Metastasis of Prostate Cancer. 100th Annual Conference of American Association For Cancer Research, April 22-26th, 2009; Denver, CO, Unites States of America (Poster)
6. **Johnson JJ**, Syed DS, Suh Y, Heren CR, Mukhtar H. Carnosol acts as a dual disruptor of both AR and ER- α expression in prostate cancer. AACR 100th Annual Meeting. April 2009; Denver, CO. (Poster)
7. **Johnson JJ**, Syed DS, Adhami, VM, Siddiqui IA, Rasmussen JT, Handa H, Mukhtar H. Dietary xanthenes for prostate cancer chemoprevention: From fruit extract to structure activity relationship studies. AACR 8th annual Frontiers in Cancer Prevention Research. December 2009; Houston TX. (Poster)
8. **Johnson JJ**, Syed DS, Adhami, VM, Siddiqui IA, Rasmussen JT, Handa H, Mukhtar H. Standardized mangosteen fruit extract promotes cell cycle arrest and apoptosis of PC3 cells and inhibits tumor formation in athymic nude mice. AACR 101st annual Meeting. April 2010; Washington, D.C. (Poster)
9. **Johnson JJ**, Syed DS, Adhami, VM, Siddiqui IA, Rasmussen JT, Mukhtar H. From fruit extract to structure activity relationship studies: Alpha-mangostin promotes G1 cell cycle arrest in PC3 cells and inhibits tumor formation in athymic nude mice. AACR 101st annual Meeting. April 2010; Washington, D.C. (Poster)
10. Li G, Petiwala SM, Pierce DR, **Johnson JJ**. Mangosteen fruit extract promotes endoplasmic reticulum stress through upregulation of CHOP/GADD153 in prostate cancer cells. Preclinical Prevention Studies 5: Targeting Novel Pathways for Prevention. AACR Annual Meeting March 31st-April 4th, 2012. Chicago, IL (Poster)
11. Petiwala SM, Li G, **Johnson JJ**. Carnosol and carnosic acid, from rosemary, promote endoplasmic reticulum stress and androgen receptor degradation in prostate cancer cells. Poster session -

Preclinical Prevention Studies 5: Targeting Novel Pathways for Prevention. AACR Annual Meeting March 31st-April 4th, 2012; Chicago, IL (Poster)

12. Li G, Ramaiya A, Pierce D, **Johnson JJ**. Mangosteen Fruit Extract promotes endoplasmic reticulum stress in prostate cancer cells. UIC Cancer Center Research Day. April 2012; Chicago, IL (Poster)
13. Petiwala SM, Li G, **Johnson JJ**. Carnosic acid from rosemary induces degradation of androgen receptor and is critically regulated by the ER stress protein CHOP. AACR Frontiers in Cancer Prevention Research Conference. October 16-19th, 2012; Anaheim, CA (Poster)
14. Thomas S, Li G, Petiwala SM, **Johnson JJ**. Evaluating the Anti-cancer and Anti-oxidant Activity of Xanthenes from the Mangosteen (*Garcinia mangostana*) Fruit. UIC Research Forum. April 16th, 2013; Chicago, IL (Poster)
15. Yan M, Li G, Petiwala SM, Householter E, **Johnson JJ**. Anti-cancer activity of rosemary extract in colon cancer cells: Involvement of Nrf2 and ERK pathways. (Translational Studies in Cancer Prevention) 105th Annual Meeting of the American Association for Cancer Research; Apr 5-9th, 2014; San Diego, CA. (Poster)
16. Petiwala SM, Berhe S, Li G, Puthenveetil AG, Nonn, **Johnson JJ**. The Mediterranean herb rosemary modulates ER stress proteins to promote androgen receptor degradation in prostate cancer cells. (Molecular Targets in Chemoprevention) 105th Annual Meeting of the American Association for Cancer Research; Apr 5-9th, 2014; San Diego, CA. (Poster)
17. Li G, Petiwala SM, **Johnson JJ**. Gartanin from the mangosteen fruit modulates androgen receptor and ER stress proteins in prostate cancer cells leading to apoptosis. (Translational Studies in Cancer Prevention) 105th Annual Meeting of the American Association for Cancer Research; Apr 5-9th, 2014; San Diego, CA. (Poster)
18. Kachawala MY, Petiwala SM, Shishkoff A, **Johnson JJ**. FGFR3 signaling in Achondroplasia - Identifying strategies for pharmacological intervention of dwarfism. UIC College of Pharmacy Research Day. February 26th, 2015; Chicago, IL (Poster)
19. **Johnson JJ**. Dosing strategies of high dose phytochemicals in the clinical setting: Plasma levels of high dose resveratrol after 84 days of administration as a case study. International Conference on Natural Products for Cancer Prevention and Therapy. August 31st, 2015; Istanbul, Turkey
20. Veenstra JP, Vemu B, **Johnson JJ**. Evaluating Mediterranean herb extracts and phytochemicals for the reversal of oxidative stress in HCT 116 colon cancer cells. University of Illinois at Chicago College of Pharmacy Research Day. February 2018. Chicago, IL (Poster)
21. Sweiss K, Calip GS, **Johnson JJ**, Jeong H, Rondelli D, Patel P. Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment-Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation. 2018 60th American Society of Hematologists Annual Meeting, December 1-4, 2018, San Diego, CA (Poster)
22. Veenstra JP, Vemu B, Guo B, Che CT, **Johnson JJ**. Evaluating the Effect of Oregano Essential Oil and Rosemary Extract on Sestrin 2 Expression in HCT 116 Colon Cells. University of Illinois at Chicago College of Pharmacy Research Day. February 2019. Chicago, IL (Poster)
23. Nauman MC, Vemu B, **Johnson JJ**. Identification of xanthenes from the mangosteen fruit that promote androgen receptor degradation. University of Illinois at Chicago College of Pharmacy Research Day. February 2019. Chicago, IL (Poster)
24. Nauman MC, Vemu B, **Johnson JJ**. "Identification of xanthenes from the mangosteen fruit that promote androgen receptor degradation." 57th annual MIKIW Medicinal Chemistry conference hosted by the

University of Kansas, April 2019. Lawrence, KS (Poster)

25. Nauman MC, Vemu B, **Johnson JJ**. "Identification of xanthenes from the mangosteen fruit that promote androgen receptor degradation." University of Illinois at Chicago Dr. Tapas Das Gupta Cancer Research Symposium, April 2019. Chicago, IL (Poster)
26. Veenstra JP, Vemu B, Nauman MC, Guo B, Che CT, **Johnson JJ**. Evaluating the effect of oregano essential oil and carvacrol on sestrin 2 Expression in HCT 116 Colon Cells. American Society of Pharmacognosy. July 2019. Madison, WI (Poster)
27. Nauman MC, Vemu B, **Johnson JJ**. Defining the role of xanthenes from the mangosteen fruit in promoting androgen receptor degradation. 67th American Society of Pharmacognosy Annual Meeting, July 2019 Madison, WI. (Poster)
28. Nauman MC, Vemu B, **Johnson JJ**. Defining the role of xanthenes from the mangosteen fruit in promoting androgen receptor degradation. 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA). September 1-5 2019. Innsbruck, Austria
29. Sweiss K, Calip GS, **Johnson JJ**, Holden J, Lewkowski P, Mialik I, Galvin GP, Rondelli D, Patel P. Low Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Receiving Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan Conditioning. 2019 62nd American Society of Hematologists Annual Meeting. December 7-10. 2019. Orlando, FL
30. Sweiss K, Vemu B, Calip GS, Galvin JP, Quigley JQ, Mahmud N, Rondelli D, **Johnson JJ**, Patel P. Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant. 2019 62nd American Society of Hematologists Annual Meeting. December 7-10. 2019. Orlando, FL
31. Sweiss K, Vemu B, Calip GS, Galvin JP, Quigley JQ, Mahmud N, Rondelli D, **Johnson JJ**, Patel P. A Real Time Pharmacokinetic Testing Method to Allow Individualized Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant. Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. February 19-23, 2020. Orlando, FL
32. Sweiss K, Calip GS, **Johnson JJ**, Holden J, Lewkowski P, Mialik I, Galvin GP, Rondelli D, Patel P Low Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Receiving Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan. Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. February 19-23, 2020. Orlando, FL
33. Veenstra JP, Vemu B, Tocmo R, **Johnson JJ**, 2020. Oil-soluble rosemary extract prevents DSS-induced colitis and improves intestinal barrier integrity. University of Illinois at Chicago College of Pharmacy Research Day. November 2020. Chicago, IL (Poster)
34. Nauman MC, Won JW, Vemu B, **Johnson JJ**. α -Mangostin from *Garcinia mangostana* fruit promotes androgen receptor degradation in prostate cancer cells through a novel protein interaction. University of Illinois at Chicago College of Pharmacy Research Day, November 2020. Chicago, IL (Poster)
35. Gurgul A, Nauman MC, **Johnson JJ**, and Che CT. Natural products from the stem of *Marsypopetalum modestum* and their cytotoxic activity. Posted delivered at virtual College of Pharmacy Research Day, University of Illinois at Chicago, November 2020. Chicago, IL (Poster)
36. Nauman MC, Won JW, Vemu B, Johnson JJ. Mangosteen Fruit Xanthenes Promote Androgen Receptor Degradation in Castration Resistant Prostate Cancer Cells." 58th Annual MIKIW Medicinal Chemistry Conference hosted by the University of Wisconsin-Madison. April 2021, Madison, WI. (Poster)
37. Nauman MC, Won JW, Vemu B, **Johnson JJ**. "Garcinia mangostana xanthenes degrade the androgen receptor in castration resistant prostate cancer cells." University of Illinois at Chicago Gary Kruh Cancer

Research Symposium. April 2021. Chicago, IL (Poster)

38. Nauman MC, Won J, Vemu B, **Johnson JJ**. Garcinia mangostana xanthenes target drug-resistant androgen receptor mutants for degradation in prostate cancer. 10th annual American Council on Medicinally Active Plants Conference hosted by Rutgers University. June 24-25, 2021. New Brunswick, NJ (Poster)
39. Tocmo R and **Johnson JJ**. Structure-activity relationship of isoprenylated xanthenes from alcoholic tinctures of Garcinia mangostana leaves and pericarp in targeting Nrf2 and iNOS. 10th annual American Council on Medicinally Active Plants Conference hosted by Rutgers University. June 24-25, 2021. New Brunswick, NJ (Poster)
40. Huang Y, Nauman MC, **Johnson JJ**. Evaluating the cholesterol lowering mechanism of bergamot (Citrus bergamia). 10th annual American Council on Medicinally Active Plants Conference hosted by Rutgers University June 24-25, 2021. New Brunswick, NJ (Poster)
41. Siblino H, Al Hendy A, Segars J, Singh B, Taylor H, Flores V, Gonzalez F, Christman G, Huang H, **Johnson JJ**, Zhang H Epigallocatechin Gallate (EGCG) for Treatment of Unexplained Infertility Associated with Uterine Fibroids (Pre-Friend Trial): Early Safety Assessment. 68th Annual Scientific Meeting for the Society for Reproductive Investigation. June 6-9, 2021. Boston, MA (Poster)
42. **Johnson JJ**, Rodriguez, RR, Patel S, Siblino H, Al Hendy A, Segars J, Singh B, Taylor H, Flores V, Gonzalez F, Christman G, Huang H, Zhang H. Development of a Novel Multiplex Pharmacokinetic Assay to Simultaneously Quantify Multiple Green Tea Catechins, Letrozole and Clomiphene in Human Plasma in the PreFRIEND Clinical Trial. 68th Annual Scientific Meeting for the Society for Reproductive Investigation. June 6-9, 2021. Boston, MA (Poster)
43. Nauman MC, Won J, Vemu B, **Johnson JJ**. Mangosteen xanthone α -mangostin promotes androgen receptor degradation through a novel protein interaction in castration resistant prostate cancer cells. Cancer Biology Annual Retreat (CABTRAC) 2021, October 24-26, 2021 Nashville, TN (Poster)
44. Nauman MC, Won J, Vemu B, **Johnson JJ**. Mangosteen xanthone α -mangostin promotes androgen receptor degradation through a novel protein interaction in castration resistant prostate cancer cells. UIC College of Pharmacy Research Day. November 12, 2021. Chicago, IL (Poster)
45. Gurgul A, Nauman MC, Bisson J, **Johnson JJ**, Che CT. A New Phenylpropanoid Glycoside and Bioactive Natural Products from Marsypopetalum modestum. UIC College of Pharmacy Research Day. November 12, 2021. Chicago, IL (Poster)
46. Rodriguez RR, Tocmo R, Gurgul A, and **Johnson JJ**. UIC College of Pharmacy Research Day. November 12, 2021. Chicago, IL (Poster)

GRANTS / FUNDING**Current / Active / Funded**

NCI R37CA227101 (PI: Johnson JJ) 01/01/2019 – 12/31/2023
***NCI MERIT Award**

Title: Defining the role of isoprenylated xanthenes from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer.

Our objective in this proposal is to identify xanthenes with the greatest potential for broad application across the prostate carcinogenesis continuum spanning diagnosis to castration resistance prostate cancer similar to anti-estrogens used to treat prostate cancer.

Role: PI

*Submitted as an R01 and selected as a R37 NCI Merit Award

Funding: \$1,926,065 (Total to PI) (Additional funding \$770,426 to 12/31/2025 following NCI administrative review).

NCI TORFP# 2020-E05 (PI: Johnson JJ / Lyubimov A) 07/01/2020 – 06/30/2022
NCI PREVENT Contract

Title: Use of Carnosic Acid and VivOX40 for Breast Cancer Prevention

The NCI PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. UIC is responsible for the pre-clinical pharmacokinetics evaluation while the in vivo efficacy will be performed by the University of Kansas.

Role: CO-PI

Funding: \$1,683,454 (Total) / \$187,565 (Total to Johnson)

3 R01 HD100367-01 (Supplement) (PI: Johnson JJ) 09/01/2020 – 08/31/2021

Title: Implications of MTHFR Polymorphisms in Women receiving a Combination of Green Tea Extract and Fertility Promoting Drugs on Serum Folate Levels

The prevalence of MTHFR mutations can range from 30 to 40% in the American population for C677T and ~50% for A1298C. Green tea extract has been reported to decrease folic acid levels through two mechanisms that include the inhibition of dihydrofolate reductase (DHFR) and decreasing the bioavailability of folic acid. Our hypothesis is that green tea catechins have weak inhibitory DHFR properties that may increase the risk of folic acid depletion in women expressing known MTHFR polymorphisms.

Role: PI

Funding: \$159,900 (Total to PI)

USDA / NIFA 2017-67017-26364 (PI: Johnson, JJ) 03/01/17 – 02/28/22

Title: Rosemary As A Preservative: Implications For Gastrointestinal Health

Our long-term goal is to determine how a rosemary extract used as a food preservative modulates Nrf2 (a major regulator of antioxidant response and inflammation), for the prevention of ulcerative colitis, to improve overall GI health.

Role: PI

Funding: \$480,000 (Total to PI)

NCI R01-00416360 (PI: Seema Khan) 02/01/19 – 01/31/2024

Title: Determinants of Transdermal Drug Delivery to the Normal and the Radiated Breast

The goal of aim 1 is to identify the variability of 4-hydroxytamoxifen drug concentrations in non-radiated breast tissue. Aim 2 will evaluate the effect of radiotherapy the effect of breast radiotherapy on drug concentrations resulting from transdermal delivery of 4-OHT; and b) identify the differences between radiated and non-radiated skin and breast tissue that contribute to differences in permeation.

Role: Co-investigator (Sub-award Consortium PI)

Funding: \$1,808,515 (Total) / \$122,270 (Total to Johnson)

Title: Pilot Study to Develop and Test a Multiplex Assay for CYP450 Phenotyping in Multiple Myeloma Patients Receiving Bortezomib.

Summary: The long term goal would be to use this validated approach of predicting CYP activity and BTZ clearance to 1) identify patients at baseline who will have higher risk of BIPN and benefit from an alternative treatment regimen, 2) identify patients who will fail to achieve therapeutic BTZ exposure with standard dosing and need higher initial doses to get deeper response rates, and finally, 3) re-assess CYP activity (since we expect it to change due to extrinsic factors) during the latter part of the treatment regimen and identify if the initial treatment plan/BTZ dose requires modification.

Role: Co-I

Funding: \$85,283 (Total to PI) / \$68,283 (Total to Johnson)

R01HD100367

(PI: Ayman Al-Hendy)

09/26/2019 – 08/31/2024

NICHD - National Institute of Child Health & Human Development

Title: Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids

The objective of this study is to conduct a randomized clinical trial to determine the effect of EGCG on fibroids and subsequent pregnancy in women seeking fertility treatment.

Role: Co-Investigator

NIAD 5R21 AI127635

(MPI: Williams/Thatcher/Petukhov)

12/01/18 - 11/30/21

Title: Identification of Preclinical Drug Candidates for the Treatment of Schistosomiasis

Aim 3: Design and synthesize novel inhibitors of TGR: A. Iterative structure and ligand-based computer-aided design; B. Medicinal chemistry: optimize for potency, stability, and oral bioavailability;

C. Structural biology: X-ray crystallography; and chemoproteomics using photoreactive probes. Aim 4:

B. Metabolic stability in plasma and mouse and human liver microsomes. Aim 5: Determine plasma concentration after IP and PO administration (the samples will be provided by Dr. Williams)

Role: Co-investigator

Funding: \$391,590 (Total to PIs) / \$32,054 (Total to Johnson)

Past Funded Projects

NCCIH / Botanical Center

(PI: Johnson, JJ)

07/01/17 – 06/30/18

Title: Induction of BiP to induce AR degradation in triple negative breast cancer

Our objective in this proposal is to evaluate phytochemicals for disrupting androgen receptor function in triple negative breast cancer.

Role: PI

Funding: \$25,000 (Total to PI)

Research Scholar Grant

(PI: Johnson, JJ)

07/01/12 – 06/30/2017

American Cancer Society(National)

Title: Prostate Cancer Chemoprevention with Carnosol by Dual Disruption of AR/ER

The goal of this research is to evaluate the dual disruption of AR and ER α with the natural product carnosol.

Role: PI

Funding: \$720,000 (Total to PI)

Hans W. Vahlteich Research Award

(PI: Johnson, JJ)

06/01/15 – 05/31/16

UIC College of Pharmacy

Title: Optimizing Xanthenes from *Garcinia mangostana* as Androgen Receptor Degradation Enhancers

The goal is to develop potent chemical analogues of gartanin and α -mangostin as androgen receptor degradation enhancers

Role: PI

Funding: \$50,000 (Total to PI)

National Institutes of Health (PI: Thatcher, G and Petukhov, P)

09/22/14 – 06/30/16

UH2HL123610 (NHLBI)

Title: Therapeutic Targeting of Carotid Body Chemoreflex for Sleep Disordered Breathing The goal is to develop inhibitors of cystathionine-gamma-lyase via high-throughput screening of chemical libraries. Johnson lab characterizes preclinical pharmacokinetics and toxicity profiles of potential lead compounds.

Role: Co-investigator

NIH Loan Repayment Program

(PI: Johnson, JJ)

7/1/11 - 6/30/15

NIH/NCI

Clinical Research - Extramural

Title: Translational Development of Natural Products for Cancer Chemoprevention

The goal of this project is to evaluate the oral delivery of α -mangostin for pharmacokinetics, safety and tolerability in mice and humans.

Role: PI

UW Comprehensive Cancer Center

(PI: Winslow, E)

08/01/14 to 07/31/15

Title: A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors

The Johnson lab will evaluate plasma levels of resveratrol inpatients receiving resveratrol after days 28, 56, and 84

Role: Co-I

5R21CA149560

(PI: Ahmad, N)

03/15/11-2/28/13

NIH/NCI

Title: Enhancing the bioavailability of resveratrol

The goal of this project is to determine if piperine enhances the oral absorption of resveratrol in healthy human volunteers. Johnson lab analyzed the plasma samples by LC-MS to determine the pharmacokinetic profile of resveratrol with and without piperine.

Role: Co-I

1R03CA138953

(PI: Johnson, JJ)

09/28/09 – 08/31/12

NIH/NCI

Title: A Dietary-Based Xanthone for Prostate Cancer Chemoprevention.

The goal of this research is to determine the effects of Mangostin for prostate cancer chemoprevention.

Role: PI

Funding: \$159,000 (Total to PI)

1KL2RR025012-01

(PI Drezner, M)

09/17/07- 05/31/10

NIH/NCRR

Title: Institutional Clinical and Translational Science Award (UW-Madison) (KL2).

The goal of the UW-ICTR is to create an environment that facilitates the transformation of research at the University into a continuum extending from investigation through discovery to translation into practice.

Role: CTSA Scholar

K12 RR02326

(PI Carnes, M)

7/1/07-9/16/07

NIH/NCRR

Roadmap K12 Program

Goals: This 5 year grant was designed to expand the nation's capacity to conduct clinical research by multidisciplinary teams. The program will emphasize research in one of 10 multidisciplinary areas of clinical research. It involves over 72 VA and UW-Madison faculty as primary mentors and an additional 100 as secondary mentors. At capacity, this will train up to 25 scholar's at one time in programs ranging from 2-5 years. NOTE: the scholars in this program have been subsumed into the UW CTSA K12 program, which was awarded 9/17/07.

Role: TEAM Scholar

PROFESSIONAL SERVICE

Study Section (Scientist Reviewer)

- 2008 Veteran Affairs (VA) Clinical Trials Study Section
Scientist Reviewer (Ad hoc)
Cancer Chemoprevention
- 2010 Czech Science Foundation
Scientific Reviewer (Ad Hoc)
- 2019 The Research, Education & Innovation Program.
[Funded by the European Regional Development Fund; Applications for pre-doctoral,
post-doctoral and early career faculty in France (Pays de la Loire)]
- 2010 – Present Department of Defense (DOD) Congressionally Directed Medical Research
Programs (CDMRP) Prostate Cancer Research Program(PCRP)
- 2010 Prostate Cancer Training Award 2
2011 Pre-application - Clinical and Experimental Therapeutics-3
2011 Training-Detection and Experimental Therapeutics
2012 Training-Detection and Experimental Therapeutics
2013 Clinical and Experimental Therapeutics-1
2014 Training - Pathobiology
2014 Pre-application-Exploration-Hypothesis Development-Clinical and Experimental
Therapeutics-1
2015 Clinical and Experimental Therapeutics
2016 Clinical and Experimental Therapeutics
2017 Clinical and Experimental Therapeutics
2018 Pre-application-Clinical and Experimental Therapeutics-1
- 2013 – Present Department of Defense (DOD) Congressionally Directed Medical Research Programs
(CDMRP) Breast Cancer Research Program (PCRP)
- 2013 Epidemiology and Prevention
2015 Epidemiology and Prevention
2018 Clinical Trial - Preclinical Research
2019 Clinical Trial - Preclinical Research
2019 Prevention
2020 Clinical and Experimental Therapeutics

Conference Committee

- 2014 Chair of Botanical Medicinal Symposium; Organizing Committee
53rd Annual Meeting of the Phytochemical Society of North America (Raleigh, NC)
August 9-13th
- 2019 Organizing Committee. 3rd International Conference on Natural Products for Cancer Prevention
and Therapy at Erciyes University. December 18-20, 2019. Kayseri, Turkey

Editorial Board

- 2019 – Present Nutrients
- 2019 – Present Integrative Molecular Medicine

Special Issues

2019 Guest Editor – Nutrients
Special Issue: Benefits of Phytochemicals

Article/Journal Reviewer (In alphabetical order)

2009 to Present Reviewer

Biochemistry / Pharmacology: AAPS; Canadian Journal of Physiology and Pharmacology; Investigational New Drugs; Journal of Pharmacy and Pharmacology; Journal of Steroid Biochemistry and Molecular Biology; Life Sciences

Cancer: Cancer Epidemiology, Biomarkers and Prevention; Carcinogenesis; Cancer Letters; Cancer Research; Clinical Cancer Research; International Journal of Cancer; Molecular Cancer

Nutrition: Food and Function; Journal of Agricultural Food Chemistry, Journal of Food Science; Journal of Nutrition; Journal of Nutritional Biochemistry; Molecular Nutrition and Food Research; Nutrients, Nutrition Research

Chemistry, Toxicology, Other: Arabian Journal of Chemistry, Biomedical Chromatography; Chemical Research in Toxicology; Environmental Toxicology and Pharmacology; Experimental Dermatology; Journal of Medicinal Chemistry; Journal of Proteome Research; Molecules; PLoSOne; Toxicology and Applied Pharmacology

University, College, Department Committees and Service

Department

1. UIC College of Pharmacy Strategic Planning, Department of Pharmacy Practice: Scholarship working group (2010)
2. Education Policy Committee, Department of Pharmacy Practice (2015 – 2019)
3. Promotion and Tenure Track Committee, Department of Pharmacy Practice (2019 – Present)
4. Faculty Mentor to Assistant Professor (2019 to Present)
5. Member Search Committee, Research Specialist (2020)
6. Member, Strategic Planning Committee (2020)
7. Co-Chair, B2F Search Committee, Department of Pharmacy Practice (2020 – 2021)
8. Member, Strategic Planning Committee, Draft Group (2020)
9. Member, Strategic Planning Committee, Objective Development Group (2020)
10. Chair Search Committee, Post-Doctoral Research Associate (2021)
11. Co-Chair, B2F Search Committee, Department of Pharmacy Practice (2021 – 2022)
12. Member, PMPR Strategic Plan Assessment, Implementation, and Monitoring (AIM)
13. Gatekeeper, PMPR Strategic Plan 2021-2025 (2021 – Present)

College

1. Member, UIC College of Pharmacy Committee on Committees (2011 – 2018)
2. Judge, UIC College of Pharmacy Research Day (2011)
3. Judge, UIC College of Pharmacy Research Day (2012)
4. Reviewer, David J. Riback Research Pre-doctoral Fellowships (2013 – 2016)
5. Member, Organization and Administration Committee (ACPE Self Study) (2013 – 2014)
6. Judge, UIC College of Pharmacy Research Day (2015)
7. Member (Elected), Executive Committee (2019 – Present)
8. Advisor/Application Reviewer, UIC ASPET Summer Undergraduate Research Fellowship (SURF) (2015 – Present)
9. Member, COP Graduate Program Review Committee (2020 – Present)
10. Member, College Restart Committee COP Research Committee on planning to reopen Research Operations (2020)
11. Co-Chair, Executive Committee Promotion and Tenure Review Committee (2020 – 2021)
12. Member, Ad-hoc Graduate Program Review Committee, College of Pharmacy (2020 – Present)
13. Co-Lead, Facilities and Resources subcommittee for ACPE PharmD Self Study (2021)
14. Member, Search Committee Director of UICENTRE (i.e. Drug Discovery Center), College of Pharmacy (2021 – Present)

15. University

1. Pre-Clinical Core Leader, UICentre, College of Pharmacy (2012 – Present)
2. UIC Faculty Senate, College of Pharmacy Representative (2012 – 2020)
3. Reviewer, UIC Cancer Center Pilot Project Program (2020)
4. Senate Representative, UIC Faculty Senate, College of Pharmacy Representative, (2020 – Present)
5. Member, UIC (UIC NHLBI CONNECTS) Research Committee, Department Representative (Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies), (2021 – Present)
6. T32 Mentor, UIC Cancer Center (2021 – Present)

TEACHING**Courses Taught at UIC**

#	Term	Course #	Course Title	Team Taught (Yes/No)	Lab Teaching (Yes/No)	# of Lectures	Credit Hours	Required/ Selective/ lective	Enrollment
1	Spring 2011	BPS553	Cancer Biology and Therapeutics	Yes	No	1	2	Elective	14
2	Spring 2011	PHAR 365	Nonprescription pharmaceuticals and herbal Medicinals	Yes	No	4	3	Required	162
3	Spring 2012	PHAR 365	Nonprescription pharmaceuticals and herbal Medicinals	Yes	No	4	3	Required	167
4	Fall 2013	MDCH 507	Drug Discovery, Design, and Development	Yes	No	1	3	Elective	21
5	Spring 2013	PMPR 355	Seminar in Pharmacy Practice	Yes	No	1	1	Elective	35
6	Spring 2013	PHAR 365	Nonprescription pharmaceuticals and herbal Medicinals	Yes	No	4	3	Required	194
	Spring 2013	BPS 553	Cancer Biology and Therapeutics	Yes	No	1	2	Elective	35
7	Spring 2014	PMPR 355	Seminar in Pharmacy Practice	Yes	No	1*	1	Elective	31
8	Spring 2014	PMPG 511	Advanced Pharmacognosy	Yes	No	3	3	Elective	5
9	Spring 2014	PHAR 365	Nonprescription pharmaceuticals and herbal Medicinals	Yes	No	3	3	Required	206
10	Fall 2014	MDCH 507	Drug Discovery, Design, and Development	Yes	No	1	3	Elective	15
11	Fall 2014	BPS 553	Cancer Biology and Therapeutics	Yes	No	1	2	Elective	7
12	Fall 2014	PMPG 510	Research Techniques in Pharmacognosy	Yes	No	3	4	Selective	4
10	Spring 2015	PMPR 355	Seminar in Pharmacy Practice	Yes	No	1*	1	Elective	10
11	Spring 2015	PHAR 365	Nonprescription pharmaceuticals and herbal Medicinals	Yes	No	3	3	Required	206
12	Fall 2016	MDCH 507	Drug Discovery, Design, and Development	Yes	No	1	3	Elective	7
13	Fall 2016	PMPG 510	Research Techniques in Pharmacognosy	Yes	No	3	4	Selective	9
14	Fall 2017	MDCH 507	Drug Discovery, Design and Development	Yes	No	1 ^a	3	Required	7
15	Spring 2017	PHAR 365	Nonprescription Pharmaceuticals and Herbal Medicinals	Yes	No	4	3	Required	197 (164 ^b /33 ^c)
16	Fall 2017	MDCH 507	Drug Discovery, Design and Development	Yes	No	1	3	Required	7
17	Fall 2017	PMPG 510	Research Techniques in Pharmacognosy	Yes	No	3	3	Selective	4
18	Fall 2017	BPS 553	Cancer Biology and Therapeutics	Yes	No	1	2	Selective	4
19	Spring 2018	PMPG 511	Advanced Pharmacognosy	Yes	No	3	3	Selective	6
20	Spring 2018	PHAR 365	Nonprescription Pharmaceuticals and Herbal Medicinals	Yes	No	4	3	Required	187 (160 ^b /27 ^c)
21	Fall 2018	PHAR 508	Pathophysiology, Drug Action, & Therapeutics (PDAT) 8: Special Topics	Yes	Yes	5 ^d	3	Required	165 (141 ^b /24 ^c)

22	Fall 2018	MDCH 507	Drug Discovery, Design and Development	Yes	No	1 ^a	3	Required	11
23	Fall 2018	PMPG 510	Research Techniques in Pharmacognosy	Yes	No	3	3	Selective	5
24	Spring 2019	PMPG 565	Special Topics: Applied Clinical Pharmacognosy I	Yes	No	5 [*]	1	Elective	15
25	Fall 2019	PHAR 508	Pathophysiology, Drug Action, & Therapeutics (PDAT) 8: Special Topics	Yes	Yes	5 ^d	3	Required	196 (160 ^b /36 ^c)
26	Fall 2019	MDCH 507	Drug Discovery, Design and Development	Yes	No	1 ^a	3	Required	8
27	Fall 2019	BPS 553	Cancer Biology and Therapeutics	Yes	No	1	2	Selective	5
28	Fall 2019	PMPG 510	Research Techniques in Pharmacognosy	Yes	No	3	3	Selective	5
29	Spring 2020	PMPG 511	Advanced Pharmacognosy	Yes	No	3	2	Selective	4
30	Fall 2020	PHAR 508	Pathophysiology, Drug Action, & Therapeutics (PDAT) 8: Special Topics	Yes	Yes	5 ^d	3	Required	194 (160 ^b /34 ^c)
31	Fall 2020	PSCI 501	Drug Discovery, Design and Development	Yes	No	2 ^a	3	Required	26
32	Fall 2020	PSCI 520	Research Techniques in Pharmacognosy	Yes	No	3	3	Required	5
33	Fall 2020	BPS 425	College of Pharmacy Colloquium Lecture Series	Yes	No	1	1	Elective	35 (25 ^b /10 ^c)
34	Spring 2021	PATH 511	Pathobiology of Cancer	Yes	No	2 ^a	3	Required	10
35	Fall 2021	PHAR 508	Pathophysiology, Drug Action, & Therapeutics (PDAT) 8: Special Topics	Yes	Yes	5 ^d	3	Required	163 (135 ^b /28 ^c)
36	Fall 2021	PSCI 501	Drug Discovery, Design and Development	Yes	No	4 ^a	3	Required	22
37	Fall 2021	PSCI 520	Research Techniques in Pharmacognosy	Yes	No	3	3	Required	6
38	Spring 2022	PATH 511	Pathobiology of Cancer	Yes	No	1 ^a	3	Required	10
39	Spring 2022	PSCI 520	Advanced Pharmacognosy	Yes	No	3 ^a	3	Required	
40	Fall 2022	PHAR 508	Pathophysiology, Drug Action, & Therapeutics (PDAT) 8: Special Topics	Yes	Yes	5 ^d	3	Required	
41	Fall 2022	PSCI 501	Drug Discovery, Design and Development	Yes	No	4 ^a	4	Required	
42	Fall 2022	PSCI 520	Research Techniques in Pharmacognosy	Yes	No	3	3	Required	

a = Each lecture is 1.5 hours

b = students enrolled in Chicago Campus

c = students enrolled in Rockford

d = Instructor and recitation leader. Responsible for 3 hours of lecture and 2 two-hour recitations (i.e. lab)

* = course coordinator

Student Evaluations

#	Semester/ Term	Course Number	Course Title	Required/ Selective/ Elective	*Average Rating + SD	(n/N)
1	Spring 2012	PHAR 365	Nonprescription pharmaceuticals and herbal medicinals	Required	4.4	164/167
2	Spring 2013	PHAR 365	Nonprescription pharmaceuticals and herbal medicinals	Required	4.4	188/194
3	Spring 2014	PHAR 365	Nonprescription pharmaceuticals and herbal medicinals	Required	4.2	200/206
4	Spring 2015	PHAR 365	Nonprescription pharmaceuticals and herbal medicinals	Required	3.9	200/206
6	Spring 2016	PHAR 365	Nonprescription pharmaceuticals and herbal medicinals	Required	3.81 ± 1.05 ^a 4.1 ± 0.91 ^b (3.87) ^c	123/157 ^a 31/36 ^b (154/193) ^d
7	Spring 2017	PHAR365	Nonprescription Pharmaceuticals & Herbal Medicinals	Required	4.0 ± 0.87 ^a 3.81 ± 1.21 ^b (3.96)	95/164 ^a 22/33 ^b (117/197) ^d
8	Spring 2018	PHAR365	Nonprescription Pharmaceuticals & Herbal Medicinals	Required	4.19 ± 0.92 ^a 4.0 ± 0.98 ^b (4.16) ^c	112/160 ^a 24/27 ^b (136/187) ^d
9	Fall 2018	PHAR508	Pathophysiology, Drug Action, and Therapeutics (PDAT) 8: Special Topics.	Required	4.7 ± 0.67 ^a 4.94 ± 0.25 ^b (4.74) ^c	93/141 ^a 16/24 ^b (109/164) ^d
10	Spring 2019	PMPG565	Special Topics: Applied Clinical Pharmacognosy I	Elective	5.0 ± 0	6/15
11	Fall 2019	PHAR508	Pathophysiology, Drug Action, and Therapeutics (PDAT) 8: Special Topics.	Required	4.51 ± 0.75 ^a 4.16 ± 0.69 ^b (4.44) ^c	144/160 ^a 32/36 ^b (176/196) ^d
12	Fall 2020	PSCI520	Research Techniques in Pharmacognosy	Selective	5.0 ± 0	4/5
13	Fall 2021	PHAR508	Pathophysiology, Drug Action, and Therapeutics (PDAT) 8: Special Topics.	Required	4.44 ± 0.86 ^a 4.6 ± 0.91 ^b () ^c	117/135 ^a 25/28 ^b 142/163 ^d

*Average of students' ratings of the "Overall Teaching Effectiveness" (or equivalent) of the candidate, on a scale of 5 (Excellent) to 1 (Poor). SD = standard deviation; n = number of students who rated the candidate in that course; N = total number of students in that course.

A = Chicago Campus

b = Rockford campus

c = weight averaged between students enrolled in Chicago

c = students enrolled in Rockford

d = Instructor and recitation leader. Responsible for 3 hours of lecture and 2 two-hour recitations (i.e. lab)

Courses Taught at the University of Wisconsin

#	Term	Course #	Course Title	Team Taught (Yes/No)	Lab Teaching (Yes/No)	# of Lectures	Credit Hours	Required/ Selective/ Elective	Enroll- ment
1	Fall 2009	Pharm Prac 672	Herbals, Homeopathy, and Dietary Supplements	Yes	No	1	3	Elective	>15*
2	Fall 2009	Pharm Prac 638	Over the Counter Medications	Yes	No	1	3	Elective	>50*

* Exact number of students enrolled is not known.

Teaching Continuing Education (Medicine and Pharmacy)

1. **Johnson JJ.** Dietary Supplements for Chemoprevention. An Update on Herbal Therapies and Nutritional Supplements. January 25, 2015. Brookfield, Wisconsin (University of Wisconsin, Continuing Education for Pharmacists)
2. **Johnson JJ.** Phytochemical Modulators of Mitochondria: The Search for New Signaling Agents and Supportive Therapeutics. Advances in Mitochondrial Medicine: A New Model for Treating Chronic Disease. October 5, 2019. George Washington University (Continuing Education for Physicians)

Mentoring

*Current positions of all trainees with LinkedIn profiles is available [here](#).

Graduate Student Advising

#	Name of Student	Beginning and Completion Dates	Degree; Thesis Title; Role (Chair, advisor, or committee member)
1	Jacob Veenstra ^a	08/2016 – 05/2021	PhD; Identification of Sestrin 2 Modulators from Rosemary (<i>Salvia rosmarinus</i>) in Colitis and Colon Cancer; Chair
2	Mirielle Nauman ^b	04/2018 – present	PhD; Identification of androgen receptor degradation enhancers from the mangosteen (<i>Garcinia mangostana</i>); Chair
3	Rocio Rivera Rodriguez ^c	04/2021 – present	PhD; Pharmacology and Pharmacokinetics of selected phytochemicals; Chair
4	Pariksha Thapa	03-2022 - present	PhD; Novel therapeutics for prostate cancer

a = Awards received by Jacob Veenstra

1. AAPS Student Chapter Award, 2nd prize Poster, University of Illinois Chicago, 2020
2. George R. Aynilian Family Fund Scholarship Award, University of Illinois Chicago, 2019

b = Awards received by Mirielle Nauman

1. Chancellor's Student Service and Leadership Award, University of Illinois Chicago, 2019
2. Graduate College Student Presenter Award, University of Illinois Chicago, 2019
3. TAPS – Travel Award for Ph.D. Students, University of Illinois at Chicago, 2019
4. Horizon-Lundbeck Award for Excellence in Research University of Illinois Chicago, 2019
5. Fulbright Semi-Finalist (Research Grant in Mexico), Universidad Nacional Autónoma de México
6. NCI T32 Pre-Doctoral Fellow, University of Illinois at Chicago, 2021
7. W.C. and May Preble Deiss Fund for Biomedical Research Award for Graduate Research, University of Illinois at Chicago, 2021
8. Gary Kruh Cancer Research Symposium - Best Poster, University of Illinois at Chicago, 2021
9. Fulbright Alternative (Research Grant in Chile), University of Illinois at Chicago, Universidad de Talca, 2021

c = Awards received by Rocio Rivera Rodriguez

1. UIC Access to Excellence Fellowship
2. UIC Research Day – 2nd Place Pharmaceutical Sciences Graduate Student Association Award for Excellence in Research

Undergraduate and Pharmacy Student AdvisingUndergraduate

#	<u>Name of Student</u>	<u>Semester and Year</u>	<u>Nature of Advising/Supervision</u> (e.g – independent study, , Honors College Fellow work Honors College Capstone)
1	Amanda Kohl	2009 – 2010	Independent Study, Xanthenes for prostate cancer
2	Dana Pierce	2011 – 2012	Independent Study, Mangosteen Extract for prostate cancer
3	Robin Varghese	2013	Independent Study, Phytochemicals for hypercholesterolemia
4	Joseph Sahagun	2014 – 2015	Honors College Capstone, Natural Products for Cancer
5	Emma Bodell	2014 – 2016	Honors College Capstone, Natural Products for Cancer
6	Daniel Soto	2015	Honors College Capstone, Mangosteen for colon cancer
7	Charles Nystrom	2015	Independent Study (Wheaton College), Mangosteen for coloncancer
8	Elise Bowler ^a	2015	ASPET SURF Fellow, Rosemary and triple negative breast cancer
9	Edwin Lee	2015 – 2016	Honors College Capstone, Novel targets in triple negative breast cancer
10	Daniel Soto	Summer 2015	Rosemary and triple negative breast cancer
11	Monica Haughan ^b	Summer 2019	SURF Mentor, Characterizing the cholesterol lowering property of bergamot

a = awards received by Elise Bowler

1. UIC ASPET SURF 1st place poster presentation, University of Illinois at Chicago

b = awards received by Monica Haughan

1. UIC ASPET SURF 1st place poster presentation, University of Illinois at Chicago

PharmD PhLAMES students

#	<u>Name of Student</u>	<u>Semester and Year</u>	<u>Nature of Advising/Supervision</u> (e.g – independent study, Honors College Capstone, Honors College Fellow work)
----------	-------------------------------	---------------------------------	---

1	Rushik Patel	Fall 2017 to Spring 2018	PhLAMES Mentor
2	Hoanghuy Dong	Fall 2017 to Spring 2019	PhLAMES Mentor
3	Matthew Wong	Fall 2017 to Spring 2020	PhLAMES Mentor
4	Kim Hyn	Fall 2017 to Spring 2021	PhLAMES Mentor
5	Natalia Wojciaczyk	Fall 2018 to Present	PhLAMES Mentor
6	Joseph Pera	Fall 2019 to Present	PhLAMES Mentor
7	Elisamary Sanchez	Fall 2020 to Present	PhLAMES Mentor
8	Dylan Bihun	Fall 2020 to Present	PhLAMES Mentor
9	Adam Elmkinssi	Fall 2021 to Present	PhLAMES Mentor

PharmD students

<u>#</u>	<u>Name of Student</u>	<u>Semester and Year</u>	<u>Nature of Advising/Supervision</u> (e.g – independent study, Honors College Capstone, Honors College Fellow work)
1	Chenelle Heren	2007	Independent Study, Carnosol for prostate cancer
2	John Rasmussen	2009 – 2010	Independent Study, Xanthones for prostate cancer
3	Emily R. Householter	2013	Independent Study Xanthones for colon cancer
4	Vin Ng	2014	Faculty Research Advisor (PMPR380) mTOR inhibitors for breast cancer
5	Anastasia Shiskoff	2014 – 2015	Faculty Research Advisor (PMPR380) Skeletal Dysplasia/drug discovery
6	Angeline (Tracy) Souvannasing	2015 – 2016	Faculty Research Advisor (PMPR380) Pharmacokinetic properties of Resveratrol
7	Matthew Hart	Fall 2019 to Spring 2019	Faculty Research Advisor (PMPR380) Isolation of natural products

Medical Students

#	<u>Name of Student</u>	<u>Semester and Year</u>	<u>Nature of Advising/Supervision</u> (e.g – independent study, Honors College Capstone, Honors College Fellow work)
1	Ozair Rahman	2011	Independent Study, Rosemary Extract for prostate cancer
2	Angela Puthenveetil	2012	Independent Study, Rosemary Extract for prostate cancer

Post-Doctoral Fellows Supervised

#	<u>Name</u>	<u>Beginning and Ending Dates</u>	<u>Nature of Supervision</u>
1	Atul Ramaiya, PhD	2011 to 2012	Primary Supervisor
2	Gongbo Li, PhD	2011 to 2014	Primary Supervisor
3	Jonghoon Wong, PhD	02/2016 to 07/2017	Primary Supervisor
4	Bhaskar Vemu, PhD	04/2016 to 04/2021	Primary Supervisor
5	Restituto Tocmo, PhD ^a	06/2019 to 09/2021	Primary Supervisor
6	Bikash Dangi, PhD	08*2021 to present	Primary Supervisor
7	Kanchan Yadav, PhD	09/2021 to 09/2022	Primary supervisor
8	Krishna Gone, PhD	09/2021 to Present	Primary Supervisor

a = Awards received by Restituto Tocmo, PhD

1. Lundbeck Award for Excellence in Research in the category Biology: Molecular & Cell Biology; Mechanism of action, 2020

Visiting Scholars

#	<u>Name of Visiting Scholars</u>	<u>Beginning and Ending Dates</u>	<u>Nature Supervision</u>
1	Saba Berhe ^a	2012	Primary Supervisor
2	Miao (Mel) Yan, PhD ^b	2013 to 2014	Primary Supervisor
3	Munira Kachwala ^c	2014 to 2016	Primary Supervisor
4	Xiaopei Tong, MS ^d	09/2018 to 03/2019	Primary Supervisor
5	Dana Jandali, PharmD	05/2019 to 11/2019	Primary Supervisor
6	Yunying Huang, PhD ^e	01/2020 to 06/2021	Primary Supervisor

a = Switzerland, University of Basel, Master's Degree Student

b = China, Second Xiangya Hospital

c = India, PhD Student

d = China, Master's Degree Student, Central South University

e = Visiting Professor, University of Guangzhou

Technicians / Research Specialists

#	<u>Name of Technicians</u>	<u>Beginning and Ending Dates</u>	<u>Nature Supervision</u>
1	Sakina M. Petiwala, MS, MS	2011 – 2016	Primary Supervisor
1	Katherine Dye, MS	09/2019 to 02/2021	Primary Supervisor
2	Shitalben Patel, MS	03/2020 to 07/2021	Primary Supervisor

Graduate Student Exam Committees *

#	<u>Academic Year</u>	<u># of Committees</u>
1	2016	1
2	2017	2
3	2018	4
4	2019	1
5	2020	3
6	2021	3

* Includes Preliminary and Thesis defense Committees

UIC COP Graduate Program: Shangwen Luo, Guan Li, Karina Szymulanska, PharmD, Daniel May, Caitlin Howell, Ryan Hitzman, Jose Colina, Julia Austin, Amanda Maldonado, Brian Guo, Zamia Siddiqui (PharmD/PhD student)

UIC COM Graduate Program: Dede Ekoue, Matthew Durst (MD/PhD student)